论文部分内容阅读
目的观察长期服用扶正抗毒丸对接受高效抗反转录病毒治疗(highly active antiretroviral therapy,HAART)艾滋病(AIDS)患者免疫重建的影响。方法将200例无症状期人类免疫缺陷病毒(HIV)感染者分为对照组(单纯HAART)和试验组(服用扶正抗毒丸满1年后,在扶正抗毒丸的基础上加入HAART);分别在治疗0、6、12个月对患者症状体征总积分和卡洛夫斯基积分(生存质量)进行评分,监测CD4+、CD4+CD45RA+、CD8+T淋巴细胞计数,治疗12个月时,计算患者免疫重建成功率。结果试验组的免疫重建成功率(77.53%)、在治率(89%)均高于对照组(成功率58.97%和在治率78%),不良反应发生率(4%)、失访率(3%)低于对照组(不良反应发生率8%、失访率12%);CD4+、CD4+CD45RA+T淋巴细胞计数与对照组相比明显增加(P<0.05),CD8+T淋巴细胞计数呈逐渐增加的趋势;症状体征总积分较对照组显著降低(P<0.001),卡洛夫斯基积分则显著升高(P<0.001)。结论无症状期HIV感染者在未行HAART前长期服用扶正抗毒丸可有效提高患者后期接受HAART时的免疫重建成功率及CD4+、CD4+CD45RA+、CD8+T淋巴细胞计数,减少不良反应发生率以及增加患者用药依从性。
Objective To observe the effect of long-term administration of Fuzheng anti-drug pill on immune reconstruction in patients with highly active antiretroviral therapy (HAART) AIDS. Methods Two hundred and seventy asymptomatic human immunodeficiency virus (HIV) infected patients were divided into control group (HAART only) and experimental group (HAART was added to Fuzheng anti - drug pill one year after taking Fuzheng anti - poison pill). The scores of symptom and symptom scores and Karovski’s score (quality of life) were scored at 0, 6 and 12 months respectively to monitor the counts of CD4 +, CD4 + CD45RA + and CD8 + T lymphocytes. After treatment for 12 months, Calculate the patient’s immune reconstruction success rate. Results The success rate of immune reconstruction in experimental group (77.53%) was significantly higher than that in control group (58.97% in success rate and 78% in control rate), 4% in adverse reaction rate (3%) were lower than those in the control group (8% of adverse reactions and 12% of those lost). The counts of CD4 +, CD4 + CD45RA + T lymphocytes were significantly increased compared with the control group (P <0.05) Cell count increased gradually. The total score of symptom and symptom was significantly lower than that of the control group (P <0.001), while the Karovski’s score was significantly higher (P <0.001). Conclusion Asymptomatic HIV-infected patients with long-term use of Fuzheng Toxin Capsule before HAART can effectively improve the success rates of immune reconstruction and CD4 +, CD4 + CD45RA + and CD8 + T lymphocyte counts and reduce the incidence of adverse reactions As well as increasing patient compliance.